Huadong Medicine (China) Investor Sentiment

000963 Stock   35.95  0.24  0.66%   
About 62% of Huadong Medicine's investor base is looking to short. The analysis of overall sentiment of trading Huadong Medicine Co stock suggests that many investors are alarmed at this time. The current market sentiment, together with Huadong Medicine's historical and current headlines, can help investors time the market. In addition, many technical investors use Huadong Medicine stock news signals to limit their universe of possible portfolio assets.
  
over two months ago at news.google.com         
Huadong Medicine Co., Ltds largest shareholders are private companies who were rewarded as market ca...
Google News at Macroaxis
over two months ago at news.google.com         
With 46 percent ownership, Heidelberg Pharma AG insiders have a lot at stake - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma - Korea Economic Daily
Google News at Macroaxis
over three months ago at news.google.com         
Declining Stock and Decent Financials Is The Market Wrong About Huadong Medicine Co., Ltd - Simply W...
Google News at Macroaxis
over three months ago at news.google.com         
Huadong Medicine Seems To Use Debt Rather Sparingly - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Innovative small molecule shows promise in obesity - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
There Are Reasons To Feel Uneasy About Huadong Medicines Returns On Capital - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Chinese drugmakers developing generic drugs of Novo Nordisks Ozempic - Reuters
Google News at Macroaxis
over six months ago at news.google.com         
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast...
Google News at Macroaxis
over six months ago at news.google.com         
Is It Smart To Buy Huadong Medicine Co., Ltd Before It Goes Ex-Dividend - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
While individual investors own 26 percent of Huadong Medicine Co., Ltd , private companies are its l...
Google News at Macroaxis
over six months ago at news.google.com         
Huadong Medicine Co., Ltd Yearly Results Just Came Out Heres What Analysts Are Forecasting For This ...
Google News at Macroaxis
over six months ago at news.google.com         
Huadong Medicine Co., Ltd Yearly Results Just Came Out Heres What Analysts Are Forecasting For ... -...
Google News at Macroaxis
over six months ago at news.google.com         
Huadong Medicine Full Year 2023 Earnings Misses Expectations - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
China advances semaglutide biosimilars, Jiuyuan seeks NMPA nod - BioWorld Online
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Huadong Medicine that are available to investors today. That information is available publicly through Huadong media outlets and privately through word of mouth or via Huadong internal channels. However, regardless of the origin, that massive amount of Huadong data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Huadong Medicine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Huadong Medicine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Huadong Medicine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Huadong Medicine alpha.

Huadong Medicine Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Huadong Medicine Co., Ltds largest shareholders are private companies who were rewarded as market cap surged CN2.7b last week - Simply Wall St
10/09/2024

Complementary Tools for Huadong Stock analysis

When running Huadong Medicine's price analysis, check to measure Huadong Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Huadong Medicine is operating at the current time. Most of Huadong Medicine's value examination focuses on studying past and present price action to predict the probability of Huadong Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Huadong Medicine's price. Additionally, you may evaluate how the addition of Huadong Medicine to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities